An eight-week preclinical study in diabetic db/db mice reported that daily oral Tazbentetol preserved retinal ganglion cell function and survival, restored synaptic protein expression, reduced markers of gliosis and cell death, and improved optic nerve myelination. According to the company, these effects occurred without changes in blood glucose, insulin resistance or body weight, implying a neuroprotective mechanism independent of metabolic control. Electrophysiological measures, including pattern electroretinogram amplitude and visual evoked potential latency, moved toward normal values.
Key Points
- Retinal ganglion cell function and survival preserved in diabetic mice
- Benefits occurred without changes in glucose, insulin resistance or weight
- Synaptic protein expression restored; optic nerve myelination improved
Longevity Analysis
Diabetic retinal damage is conventionally framed as a vascular complication, yet neural degeneration in the retina begins before visible microvascular change and progresses even when glucose is well managed. A compound acting at the synapse rather than on circulating glucose separates the question of metabolic control from the question of neural tissue preservation — relevant to anyone tracking visual function, nerve conduction and regenerative capacity as markers of central nervous system aging. The retina remains the most accessible window onto neurodegeneration anywhere in the body, and electrophysiological measures of it offer an early, quantifiable signal long before symptoms declare themselves.
Original published by LT Wire.